Radequinil

Radequinil
	File:Radequinil.svg
Systematic (IUPAC) name
	5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
Clinical data
Identifiers
CAS Registry Number	219846-31-8
ATC code	None
PubChem	CID 22714308
ChemSpider	11584471
Chemical data
Formula	C18H14N4O3
Molecular mass	334.329 g/mol
	SMILES COc1cccc(c1)c3nccc2NC(=O)\C(=C/c23)c4nc(C)on4;
	InChI InChI=1S/C18H14N4O3/c1-10-20-17(22-25-10)14-9-13-15(21-18(14)23)6-7-19-16(13)11-4-3-5-12(8-11)24-2/h3-9H,1-2H3,(H,21,23) ; Key:JQOFKKWHXGQABB-UHFFFAOYSA-N ;

</th></tr>

Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABA_A receptor.^[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.^[1]^[2]

References

^ ^a ^b Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer’s Disease" (PDF). The Open Neuropsychopharmacology Journal 1: 19–23.
^ Pogacic, Vanda; Herling, Paul (2007). "List of Drugs in Development for Neurodegenerative Diseases". Neurodegenerative Diseases 4 (6): 443486. ISSN 1660-2862. doi:10.1159/000107705.

Lua error in package.lua at line 80: module 'Module:Buffer' not found.